Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Blended Treatment för PTSD: A New Format of Computer-Assisted Trauma-Focused Cognitive Behavioral Therapy

NCT05758987 · tracked via the Priya Life Science Sweden tracker
Phase
Not applicable
Started
2023-03-10
Last updated
2025-12-26

Condition(s) studied

PTSDCBT

Investigational drug(s) / intervention(s)

Blended Trauma focused Cognitive Behavioral Therapy (B-Tf-CBT)Prolonged exposure

Blended Trauma focused Cognitive Behavioral Therapy (B-Tf-CBT): A trauma-focused CBT where internet-based treatment is blended with face-to-face sessions with a therapist.

Prolonged exposure: A gold standard trauma-focused CBT delivered with face-to-face sessions with a therapist.

Study summary

A Randomized Controlled Non-inferiority Trial testing if the new experimental Blended Trauma focused cognitive behavioral therapy (B-TF-CBT) for post traumatic stress disorder (PTSD), is non-inferior to gold standard control treatment Prolonged Exposure (PE).

Research question and hypothesis

Primary

1. Is bTF-CT non-inferior to prolonged exposure (PE) when delivered in routine clinical care in terms of PTSD symptoms on the PCL-5 post-treatment?

Secondary:
2. Is bTF-CT non-inferior to prolonged exposure (PE) when delivered in routine clinical care in terms of PTSD symptoms on the PCL-5 at 6 and 12 months follow up?
3. Are there significant differences between bTF-CT and PE when delivered in routine clinical care in terms of depression, anxiety, insomnia, functionality, complex PTSD, other PTSD-measures and treatment satisfaction post-treatment and at 6 and 12 months follow up?

The study will be conducted at 3-6 outpatient clinics in Region Stockholm, Sweden.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * PTSD according to Diagnostic and Statistical Manual of mental disorders 5 as primary problem * ≥ 18 years * Basic knowledge of speaking and writing Swedish * No other psychological treatment at the same time * No ongoing threats or violence * If antidepressant medication, stable dose 6 weeks before starting treatment * Have access to the internet and a computer * Willingness/ability to participate after receiving information about what participation entails Exclusion Criteria: * Other diagnosis or problem is assessed as primary to PTSD * Moderate to severe suicidal risk * PTSD from childhood trauma that the person cannot remember

Primary outcome measure(s)

  • The Posttraumatic stress disorder checklist 5 (PCL-5) — Change from pre intervention to immediately post intervention
    Self rated PTSD-symptoms. Minimum value 0, maximum value 80, where higher values indicate more PTSD symptoms.
  • The Posttraumatic stress disorder checklist 5 (PCL-5) — Change from pre intervention to 6 months post intervention
    Self rated PTSD-symptoms. Minimum value 0, maximum value 80, where higher values indicate more PTSD symptoms.
  • The Posttraumatic stress disorder checklist 5 (PCL-5) — Change from pre intervention to 12 months post intervention
    Self rated PTSD-symptoms. Minimum value 0, maximum value 80, where higher values indicate more PTSD symptoms.

Trial sites (1)

FacilityCityRegionStatus
Karolinska Institutet Stockholm Sweden Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05758987 on ClinicalTrials.gov ↗ ← All trials in Sweden